Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Sonoma Pharmaceuticals (SNOA) Gross Profit (2016 - 2025)

Sonoma Pharmaceuticals has reported Gross Profit over the past 16 years, most recently at $1.6 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 29.92% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $6.8 million, up 34.49%, while the annual FY2025 figure was $5.5 million, 15.17% up from the prior year.
  • Gross Profit for Q4 2025 was $1.6 million at Sonoma Pharmaceuticals, down from $2.1 million in the prior quarter.
  • Over five years, Gross Profit peaked at $2.1 million in Q3 2025 and troughed at -$194000.0 in Q1 2021.
  • A 5-year average of $1.2 million and a median of $1.3 million in 2024 define the central range for Gross Profit.
  • Biggest five-year swings in Gross Profit: crashed 111.74% in 2021 and later surged 800.0% in 2023.
  • Year by year, Gross Profit stood at $1.2 million in 2021, then crashed by 30.92% to $831000.0 in 2022, then soared by 75.69% to $1.5 million in 2023, then fell by 13.01% to $1.3 million in 2024, then grew by 29.92% to $1.6 million in 2025.
  • Business Quant data shows Gross Profit for SNOA at $1.6 million in Q4 2025, $2.1 million in Q3 2025, and $1.5 million in Q2 2025.